Defining a longevity biotechnology company

Nicola Boekstein,Nir Barzilai,André Bertram,Joe Betts-LaCroix,Kristen Fortney,Stephen B. Helliwell,Michael Hufford,Joan Mannick,Jerry McLaughlin,Jim Mellon,Eric Morgen,Nils Regge,Daisy A. Robinton,David A. Sinclair,Sergey Young,Risa Starr,Alex Zhavoronkov,James Peyer

DOI: https://doi.org/10.1038/s41587-023-01854-0

IF: 46.9

2023-06-27

Nature Biotechnology

Abstract:Basic research on the biology of aging has resulted in the discovery of more than 75 interventions that extend lifespan in rodents and many more that extend lifespan in Drosophila and Caenorhabditis elegans 1,2,3,4,5,6,7,8,9,10 . The progression of this work to human trials was historically delayed by the misconception that interventions originally identified to extend rodent lifespan lacked a feasible translation strategy or were unattractive investment opportunities for investors and pharmaceutical companies. In the last 5 years, however, efforts to move those interventions into human experimentation have come to fruition. The biotechnology companies developing such treatments have created a new field of biopharmaceutical development: longevity biotechnology. Because longevity biotechnology represents a paradigm shift in therapeutic approach and faces unique challenges from the standpoint of clinical development, path to approval and patient population, it makes sense to define this rapidly advancing field and articulate standards that identify its bona fide constituents. The Longevity Biotechnology Association (LBA) is a non-profit organization created to foster collaboration, propose guidelines for industry, educate stakeholders and translate geroscience to prevent the diseases associated with aging and extend healthspan.

biotechnology & applied microbiology